Home / Market News / $LABT
benzinga Corporate Catalyst Impact 65/100 ● positive

Lakewood-Amedex Biotherapeutics Presents Research Highlighting Antimicrobial Profile Of Nu-3, Lead Clinical Candidate, At IDWeek 2026; Topline Data From Trial Expected In Q1 2027

Oct 21, 2026, 12:08 PM UTC · Primary ticker $LABT

Lakewood-Amedex Biotherapeutics presented research on its lead candidate, Nu-3, highlighting its broad-spectrum antimicrobial activity against resistant pathogens, particularly for diabetic foot ulcers. This presentation provides an update on the drug's profile and sets expectations for Phase 2a clinical trial data in Q1 2027, which will be a more significant catalyst.

Lakewood-Amedex Biotherapeutics (LABT) announced the presentation of research on its lead clinical candidate, Nu-3, at IDWeek 2026. The research highlights Nu-3's rapid and broad-spectrum bactericidal activity against resistant pathogens, including those relevant to infected diabetic foot ulcers (iDFU). This is a positive, but not immediately market-moving, update as it's a research presentation rather than new clinical trial results. The more significant catalyst for LABT will be the topline data from the ongoing Phase 2a clinical trial for iDFU, which is expected in Q1 2027. This future data release carries higher risk and opportunity for traders, as it will provide initial efficacy and safety insights from human trials.

$LABT positive Positive research presentation, upcoming trial data
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.